Search

everythinglearnresearchcommunity

for

Search:↓

How Pyrilutamide, a hair loss treatment, has improved texture and regrowth of hair without any side effects for users, who are encouraged to post progress photos.

Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.

After experiencing hair loss due to alopecia areata following COVID-19 vaccination and infection, the individual saw improvement with steroid treatments and Olumiant. They paused Olumiant during a second COVID-19 infection and expressed concern about potential hair loss flare-ups.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.

The user aims to achieve a hypertrichosis look and has used topical Minoxidil for 20 years, now trying oral Minoxidil in a low dose. They seek alternatives to Minoxidil to avoid side effects.

The post discusses a user's 2-month progress in treating hair loss using topical Du once a week, microneedling, and red light therapy. The user notes that red light therapy is primarily for face and body inflammation but also applies it to the scalp.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The user experienced hair loss while using finasteride for over 2 years, but saw slight improvement after switching to dutasteride. They also started using a scalp moisturizer for seborrheic dermatitis, which may have contributed to the hair regrowth.

An 18-year-old has been using minoxidil and finasteride for hair loss since age 15, recently adding dutasteride and GHK-Cu, but sees no significant improvement and is considering a hair transplant. Concerns are raised about using hormone suppressors at a young age, with suggestions to explore other treatments like dermarolling, diet changes, and checking for deficiencies.

The user underwent a DHI hair transplant with 3,066 grafts at Hairtec in the Netherlands and is using finasteride and minoxidil to restore hair, particularly at the crown. They plan to adjust minoxidil dosage and consult with a dermatologist in September.

The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.

The user shared their 2-year progress using finasteride and minoxidil, with significant improvement after adding dutasteride in the last year. They advise persistence with the treatment despite initial setbacks.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

A 26-year-old male with high testosterone is experiencing diffuse hair thinning despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, RU58841, ketoconazole shampoo, microneedling, and low-level laser therapy. Suggestions include adjusting dutasteride dosage, monitoring iron levels, and consulting a dermatologist for further evaluation.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

The conversation is about a user who had a hair transplant with 2,850 grafts and switched from finasteride and topical minoxidil to oral minoxidil and dutasteride for better results. They are hopeful for full results in a year.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

A 36-year-old has been using oral finasteride (1 mg daily) and topical minoxidil twice a day since September 2023, and added LLLT (helmet) to their routine 2 months ago, seeing positive changes. They also use Ketoconazole shampoo, rotate other medical shampoos, train regularly, eat clean, and manage stress.

The conversation is about whether treatments like finasteride, dutasteride, and minoxidil can make single hair follicles produce multiple hairs again. The user is curious if these medications can thicken hair and prolong the growth phase.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

A female experienced hair loss due to low iron and an undiagnosed thyroid issue, specifically Hashimoto's, and saw improvement after starting thyroid medication, iron supplements, and making lifestyle changes. She emphasizes the importance of addressing the root cause and shares her journey to regrowth and emotional recovery.

Tocotrienols are being discussed as a potential treatment for hair regrowth, but users report no noticeable effects after several months of use. Some users are combining tocotrienols with other treatments like pumpkin seed oil and peppermint and rosemary oil.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

The user has been using finasteride for two years without results and recently started a new routine involving derma stamping, retinol, and minoxidil, which seems to show progress. The user microneedles about half the week and uses L’Oréal night serum for retinol.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

This post and conversation are about the molecular mechanisms triggered by microneedling, specifically its effects on inflammation, tissue remodeling, epithelial proliferation, differentiation, and collagen synthesis. The discussion highlights the potential benefits of microneedling for hair loss treatment.